<DOC>
	<DOCNO>NCT01750216</DOCNO>
	<brief_summary>This observational study evaluate predictive value rapid virological response ( RVR ) early virological response ( EVR ) sustain virological response ( SVR ) stage liver fibrosis treatment-naïve patient chronic hepatitis C genotype 1 initiated treatment Pegasys ( peginterferon alfa-2a ) Copegus ( ribavirin ) . Patients follow 48 week treatment 24 week follow-up .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Copegus ( Ribavirin ) Predictive Values RVR Sustained Virological Response Different Stages Liver Fibrosis Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic hepatitis C genotype 1 Treatmentnaïve , i.e . previously treat pegylated interferon , standard interferon ribavirin Confirmed serum positive HCV RNA Liver fibrosis confirm histologically fibroscan 24 month treatment Any contraindication accord Summary Product Characteristics Pegasys Copegus Coinfection hepatitis B HIV Posttransplant patient End stage renal disease ( creatinine clearance &lt; 15 ml/min ) Patients treat immunotherapy Pregnant woman male partner woman pregnant Female patient childbearing potential male patient female partner childbearing potential unable unwilling use effective continuous contraception treatment 4 month ( female ) 7 month ( male ) thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>